JP4813461B2 - Ｐｐａｒデルタモジュレーターとしての１，３，４−オキサジアゾール−２−オン、および、それらの使用 - Google Patents

Ｐｐａｒデルタモジュレーターとしての１，３，４−オキサジアゾール−２−オン、および、それらの使用 Download PDF

Info

Publication number
JP4813461B2
JP4813461B2 JP2007506541A JP2007506541A JP4813461B2 JP 4813461 B2 JP4813461 B2 JP 4813461B2 JP 2007506541 A JP2007506541 A JP 2007506541A JP 2007506541 A JP2007506541 A JP 2007506541A JP 4813461 B2 JP4813461 B2 JP 4813461B2
Authority
JP
Japan
Prior art keywords
compound
alkyl
acid
cells
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007506541A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007531764A5 (enExample
JP2007531764A (ja
Inventor
ダニエル・ジー・マガリー
ヨッヘン・ゲルリッツァー
シュテファーニエ・カイル
カレン・チャンドロス
ジーン・メリル
ヴォルフガング・ヴェントラー
Original Assignee
アベンティス・ファーマスーティカルズ・インコーポレイテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アベンティス・ファーマスーティカルズ・インコーポレイテツド filed Critical アベンティス・ファーマスーティカルズ・インコーポレイテツド
Publication of JP2007531764A publication Critical patent/JP2007531764A/ja
Publication of JP2007531764A5 publication Critical patent/JP2007531764A5/ja
Application granted granted Critical
Publication of JP4813461B2 publication Critical patent/JP4813461B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2007506541A 2004-04-01 2005-03-30 Ｐｐａｒデルタモジュレーターとしての１，３，４−オキサジアゾール−２−オン、および、それらの使用 Expired - Fee Related JP4813461B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55842004P 2004-04-01 2004-04-01
US60/558,420 2004-04-01
PCT/US2005/010855 WO2005097763A2 (en) 2004-04-01 2005-03-30 1,3,4-oxadiazol-2-ones as ppar delta

Publications (3)

Publication Number Publication Date
JP2007531764A JP2007531764A (ja) 2007-11-08
JP2007531764A5 JP2007531764A5 (enExample) 2008-04-17
JP4813461B2 true JP4813461B2 (ja) 2011-11-09

Family

ID=34972960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007506541A Expired - Fee Related JP4813461B2 (ja) 2004-04-01 2005-03-30 Ｐｐａｒデルタモジュレーターとしての１，３，４−オキサジアゾール−２−オン、および、それらの使用

Country Status (15)

Country Link
US (2) US7638539B2 (enExample)
EP (1) EP1781648A2 (enExample)
JP (1) JP4813461B2 (enExample)
CN (1) CN1956984B (enExample)
AU (1) AU2005230838A1 (enExample)
BR (1) BRPI0508180A (enExample)
CA (1) CA2561230A1 (enExample)
IL (1) IL178166A0 (enExample)
MA (1) MA28563B1 (enExample)
NO (1) NO20064951L (enExample)
NZ (1) NZ549823A (enExample)
RU (1) RU2365589C2 (enExample)
SG (1) SG151336A1 (enExample)
WO (1) WO2005097763A2 (enExample)
ZA (1) ZA200607852B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2561738A1 (en) * 2004-04-01 2005-10-20 Aventis Pharmaceuticals Inc. 1,3,4-oxadiazol-2-ones as ppar delta modulators_and their use thereof
CA2561230A1 (en) * 2004-04-01 2005-10-20 Aventis Pharmaceuticals Inc. 1,3,4-oxadiazol-2-ones as ppar delta modulators and their use thereof
EP1745014B1 (en) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
WO2005105726A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
EP2298742B1 (en) 2005-06-30 2014-01-08 High Point Pharmaceuticals, LLC phenoxy acetic acids as PPAR delta activators
RU2008112198A (ru) 2005-09-29 2009-10-10 Санофи-Авентис (Fr) Производные фенил-1,2,4-оксадиазолона, способы их получения и их применение в качестве фармацевтических средств
EP2386540A1 (en) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
BRPI1107312B1 (pt) * 2011-11-25 2021-09-08 Universidade Federal De Santa Catarina Composto de acil-hidrazona
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
KR101715127B1 (ko) * 2015-10-30 2017-03-15 한국과학기술연구원 시신경 척수염 예방 또는 치료용 피리미딘 카복실레이트 유도체
WO2021092279A1 (en) * 2019-11-06 2021-05-14 Board Of Regents, The University Of Texas System Methods for the treatment of dysmyelinating/demyelinating diseases
CN114195786B (zh) * 2020-09-18 2023-08-22 凯思凯迪（上海）医药科技有限公司 新型fxr小分子激动剂制备及其用途
CN114195777B (zh) * 2020-09-18 2023-06-20 凯思凯迪（上海）医药科技有限公司 新型fxr小分子激动剂制备及其用途
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01143856A (ja) * 1987-09-30 1989-06-06 American Home Prod Corp 抗アレルギーおよび抗炎症剤用２−アリール置換複素環式化合物
JPH10508030A (ja) * 1994-11-01 1998-08-04 イーライ・リリー・アンド・カンパニー 経口高血糖症薬
JP2003502370A (ja) * 1999-06-18 2003-01-21 メルク エンド カムパニー インコーポレーテッド アリールチアゾリジンジオン誘導体およびアリールオキサゾリジンジオン誘導体
JP2004168768A (ja) * 2002-11-01 2004-06-17 Takeda Chem Ind Ltd 神経障害の予防・治療剤
JP2007531763A (ja) * 2004-04-01 2007-11-08 アベンティス・ファーマスーティカルズ・インコーポレイテツド ＰＰＡＲδモジュレーターとしての１，３，４−オキサジアゾール−２−オン及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5103014A (en) * 1987-09-30 1992-04-07 American Home Products Corporation Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
US4895953A (en) * 1987-09-30 1990-01-23 American Home Products Corporation 2-Aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
JP2003508529A (ja) * 1999-09-08 2003-03-04 グラクソ グループ リミテッド オキサゾールｐｐａｒ拮抗薬
CA2407587A1 (en) * 2000-04-28 2001-11-08 Sankyo Company, Limited Ppar.gamma. modulators
CA2561230A1 (en) * 2004-04-01 2005-10-20 Aventis Pharmaceuticals Inc. 1,3,4-oxadiazol-2-ones as ppar delta modulators and their use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01143856A (ja) * 1987-09-30 1989-06-06 American Home Prod Corp 抗アレルギーおよび抗炎症剤用２−アリール置換複素環式化合物
JPH10508030A (ja) * 1994-11-01 1998-08-04 イーライ・リリー・アンド・カンパニー 経口高血糖症薬
JP2003502370A (ja) * 1999-06-18 2003-01-21 メルク エンド カムパニー インコーポレーテッド アリールチアゾリジンジオン誘導体およびアリールオキサゾリジンジオン誘導体
JP2004168768A (ja) * 2002-11-01 2004-06-17 Takeda Chem Ind Ltd 神経障害の予防・治療剤
JP2007531763A (ja) * 2004-04-01 2007-11-08 アベンティス・ファーマスーティカルズ・インコーポレイテツド ＰＰＡＲδモジュレーターとしての１，３，４−オキサジアゾール−２−オン及びその使用

Also Published As

Publication number Publication date
WO2005097763A2 (en) 2005-10-20
WO2005097763A3 (en) 2005-12-15
MA28563B1 (fr) 2007-04-03
IL178166A0 (en) 2006-12-31
CN1956984A (zh) 2007-05-02
US7638539B2 (en) 2009-12-29
RU2365589C2 (ru) 2009-08-27
CN1956984B (zh) 2010-06-09
US20090275621A1 (en) 2009-11-05
US20070099964A1 (en) 2007-05-03
NZ549823A (en) 2009-12-24
BRPI0508180A (pt) 2007-08-07
JP2007531764A (ja) 2007-11-08
RU2006138494A (ru) 2008-05-10
AU2005230838A1 (en) 2005-10-20
ZA200607852B (en) 2008-07-30
SG151336A1 (en) 2009-04-30
US7872032B2 (en) 2011-01-18
NO20064951L (no) 2006-10-30
CA2561230A1 (en) 2005-10-20
EP1781648A2 (en) 2007-05-09

Similar Documents

Publication Publication Date Title
US7872032B2 (en) 1, 3, 4-oxadiazol-2-ones as PPAR delta modulators and their use thereof
JP7258763B2 (ja) ファルネソイドｘ受容体アゴニストおよびその使用
JP7243959B2 (ja) イソオキサゾール誘導体、その製造方法、及びその使用
TWI833805B (zh) 類法尼醇x(farnesoid x)受體促效劑及其用途
JP2018532772A (ja) ファルネソイドｘ受容体アゴニストおよびそれらの使用
JP2018536015A (ja) ファルネソイドｘ受容体アゴニストとその使用
JP2018536016A (ja) ファルネソイドｘ受容体アゴニストとその使用
JP4813460B2 (ja) ＰＰＡＲδモジュレーターとしての１，３，４−オキサジアゾール−２−オン及びその使用
WO2009111943A1 (zh) 用作雌激素相关受体调节剂的化合物及其应用
CN112165940A (zh) Ox2r化合物
AU2019208634B2 (en) Dihydroindolizinone derivative
WO2023195669A1 (ko) 신규한 벤조사이오펜 유도체 및 bet 억제제로서의 용도
MXPA06011064A (es) 1,3,4-oxadiazol-2-onas como moduladores de ppardelta y su uso
KR20070021171A (ko) Ｐｐａｒ 델타 조절물질로서의 1,3,4-옥사디아졸-2-온
MXPA06010935A (en) 1,3,4-oxadiazol-2-ones as ppar delta modulators
JP2024511518A (ja) ピラゾロピリミジノン化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080229

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110415

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110715

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110816

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110824

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140902

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees